allergan inc (AGN) Key Developments
Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Litigation against Allergan Inc
Jan 22 15
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announced that class action litigation has been brought on behalf of those who sold the common stock of Allergan Inc. between February 25, 2014 and April 21, 2014, inclusive. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. The complaint alleges that Valeant unlawfully tipped Pershing Square about its plan to make a tender offer for Allergan. Pershing Square then allegedly traded on this material, non-public information by purchasing an approximately 9.7% stake in Allergan during the Class Period, without first disclosing Valeant's plan to pursue a tender offer to acquire Allergan at a significant premium.
The Shareholders Foundation, Inc. Files Lawsuit against Allergan, Inc
Dec 17 14
The Shareholders Foundation Inc. announced that a lawsuit was filed on behalf of investors who SOLD shares of Allergan Inc. between February 25, 2014 and April 21, 2014, over alleged Violations of Federal Securities Laws Violations by Pershing Square Capital Management, L.P, William A. Ackman, and Valeant Pharmaceuticals International Inc. The plaintiff claims that by purchasing Allergan Inc. stock with material, non-public information between February 25, 2014 and April 21, 2014, and by communicating material, non-public information, defendants violated the Securities Exchange Act of 1934.
Allergan Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 through Jan-11-2015
Dec 3 14
Allergan Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 through Jan-11-2015. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Presentation Date & Speakers: Jan-10-2015, David E. I. Pyott, Chairman and Chief Executive Officer. Jan-11-2015, David E. I. Pyott, Chairman and Chief Executive Officer.
Shareholders Claim Allergan Inc.'s Board of Directors Adopted Poison Pill to Avoid Acquisition
Nov 30 14
The shareholders in Allergan Inc. filed a lawsuit alleging the company's board of directors failed to properly consider a buyout offer of the company by Valeant Pharmaceuticals International Inc. and Pershing Square. The plaintiffs allege the proposed acquisition would have been worth up to $59 billion to Allergan shareholders. The complaint claims the defendants ignored the advice of Goldman Sachs, the company's investment banker, to investigate the offer and, instead, adopted bylaw provisions to entrench themselves in the company and protect their own interests. Valeant and Pershing Square also filed a counterclaim against Allergan, alleging the company's tactic of seeking to ward off an acquisition by soliciting opposition from their shareholders without filing a proxy statement violates federal securities law. The complaint alleges the defendants engaged in self-dealing and names several Allergan directors, as well as David E.I. Pyott, the board's chairman and the company's CEO, as defendants.
Actavis plc, Allergan Inc. - M&A Call
Nov 17 14
To discuss the acquisition of Allergan by Actavis